Peculiarities of chemo-resistant HIV/AIDS-associated tuberculosis in patients who died from co-infection
DOI:
https://doi.org/10.14739/2310-1237.2013.1.15363Keywords:
chemoresistance of HIV/AIDS-associated tuberculosisAbstract
Introduction. Today the problem of spread of two epidemics - TB and HIV/AIDS is too complicated in Ukraine. This problem is significantly complicated by the spread of the other world's problem - resistant TB. The growth of the HIV epidemic influences the situation of multidrug-resistant tuberculosis (MRTB), which is also associated with disorders of antituberculosis immunity. According to the literature, the high incidence of MRTB is directly correlated with the prevalence of HIV infection and AIDS. Tuberculosis is the direct cause of death of up to 30.0% of patients with HIV infection and in 90.0% cases of AIDS. That’s why studying the clinical course of HIV/AIDS-associated tuberculosis and analysis of causes of death of these patients are highly actual today.
The aim of the study. To determine the clinical course and causes of death in patients with chemo-resistant HIV/AIDS-associated tuberculosis.
Materials and methods. 14 patients cards who died from chemo-resistant HIV/AIDS-associated tuberculosis and who were supervised and treated at Zaporizhzhya TB dispensaries during the period of 2010-2012 are analyzed in this article.
The results of research. Among patients with chemo-resistant HIV/AIDS-associated tuberculosis there were 12 men (85.7%) and 2 (14.3%) women. The average age was 41.9 ± 1.8 years. There were 100% of unemployed patients, 8 patients (57.1%) were former prisoners, 4 (28.5%) patients were shelterless persons, 4 patients (28,5%) suffered from drug addiction and alcoholism. Antisocial lifestyle was in 8 (57.1%) cases. HIV-infection started significantly (P <0.05) more often after tuberculosis (in 8 patients (57.1%), before tuberculosis - in 2 (14,4%) patients, the simultaneous detection of co-infection was found in 4 cases (28,5%).
Chemo-resistant HIV/AIDS-associated tuberculosis was found in patients with primarily diagnosed HIV/AIDS-associated tuberculosis in 2 cases (14.3%), with recurrent tuberculosis – in 2 (14.3%), with chronic tuberculosis - in 10 (71.4%). As it was noticed, the chronic process prevailed significantly (P <0.05) in patients who died from resistant co-infection. Among patients with MRTB patients who were resistant to 6-9 antitubercular drugs prevailed - 8 cases (66.7%), compared with patients with resistance to 4-5 antitubercular drugs - in 4 cases (33.3%).
Among patients with chemo-resistant HIV/AIDS-associated tuberculosis disseminated (57.3%) and fibro-cavernous forms of lungs tuberculosis (28.5%) prevailed significantly (P <0.05) more often.
There are 3 patients (13.6%), who interrupted treatment, 1 patient refused treatment completely. Antiretroviral therapy was received by 4 patients (28.5%), 1 patient (7,1%) renounced, in 9 cases (64.4%) - antiretroviral therapy was not intended.
The autopsy determined that 14 (100%) patients died due to progression of tuberculosis.
Conclusion. It was determined that most of the patients lived the anti-social way of life, and suffered from alcoholism or drug addiction. More often co-infected patients with chemo-drug resistant tuberculosis suffered from tuberculosis earlier, than from HIV, most of the patients had chronic tuberculosis. They had interruptions and failures in previous treatment; most of the patients who died from co-infection had MRTB with resistance to 8-9 anti-TB drugs and all of those patients had pulmonary tuberculosis and predominantly disseminated and fibro-cavernous forms, they had a low level of CD4+ cell. Most patients had noncompliance with a specific anti-TB and antiretroviral treatment and did not receive preventive treatment.
References
Александров О.В. ВІЛ та туберкульоз: проблеми та шляхи їх вирішення [Текст] / Александров О.В. // Доповідь на науково-практичному семінарі «Проблеми фтизіатрії в Запорізькій області та шляхи їх подолання» – Запоріжжя, 2008.
Андрейчин М.А. Інфекційні хвороби в загальній практиці та сімейній медицині / Андрейчин М.А. – Тернопіль: Укрмедкнига, 2007. – 500 с.
Волкова К.И. Туберкулез в период эпидемии ВИЧ/СПИДа и наркомании / Волкова К.И., Кокосов А.Н., Браженко Н.А. // Проблемы туберкулеза. – 2001. – №2. – С. 61–65.
Динаміка захворюваності та смертності від туберкульозу до і під час епідемії: тенденції та регіональні особливості / Мельник В.М. [та ін.] // Укр. пульмонол. журнал. – 2006. – №1. – С. 53–55.
Зайцева С.И. Клиника и профилактика туберкулеза у ВИЧ-инфицированных / Зайцева С.И., Матвеева С.Л., Ющенко Л.П. // Международный мед. журнал. – 2002. – №4. – С. 29–33.
Мельник В.П. Захворюваність та летальність хворих на туберкульоз у поєднанні з ВІЛ-інфікуванням та СНІДом / Мельник В.П., Світлична Т.Г. // Укр. пульмонол. журнал. – 2006. – №2. – С. 34–36.
Нечаева О.Б. ВИЧ-инфекция и туберкулез / Нечаева О.Б., Антонова Н.В. // Здравоохранение Российской Федерации. – 2003. – №2. – С. 33–35.
Показатели иммунитета у пациентов с ВИЧ-инфекцией, ассоциированной с туберкулезом на разных стадиях заболевания / С.А. Сотниченко [и др.] // Дальневосточный медицинский журнал. – 2008. – №1. – С. 62–65.
Профіль медикаментозної резистентності МБТ до протитуберкульозних препаратів у хворих на мультирезистентний туберкульоз та туберкульоз із розширеною резистентністю МТБ залежно від випадку захворювання / Н.А. Литвиненко [та ін.] // Туберкульоз, легеневі хвороби, ВІЛ-інфекція. – 2012. – №4. – С. 85–91.
Світлична Т.Г. Епідеміологічний нагляд та ефективність лікування хворих на ВІЛ/СНІД-асоційований туберкульоз / Світлична Т.Г., Єфименко Л.В. // Актуальні проблеми медицини та біології. – 2007. – №1 (35). – С. 182–187.
Туберкулез у ВИЧ-инфицированных и больных СПИДом / А.Г. Рахманова [и др.] // Клиническая медицина. – 2003. – №12. – С. 71–73.
Фещенко, Ю.І. Сучасні погляди на епідситуацію з туберкульозу в Україні / Фещенко Ю.І., Мельник В.П. // Укра. пульмонол. журнал. – 2007. – №2. – С. 75–80.
Черенько С.О. Епідеміологічний нагляд за ситуацією щодо захворюваності на туберкульоз та ВІЛ/СНІД в Україні / Черенько С.О., Александріна Т.А. // Український медичний часопис. – 2004. – №3 (41). – С. 69–72.
Щелканова А.И. Особенности течения туберкулеза, сочетанного с ВИЧ-инфекцией / Щелканова А.И., Кравченко А.В. // Терапевтический архив. – 2004. – №4. – С. 20–24.
Эффективность лечения больных туберкулезом легких, выделяющих микобактерии с лекарственной устойчивостью к основным и резервным противотуберкулезным препаратам (XDR) / О.Г. Комиссарова [и др.] // Материалы 8 Российского съезда фтизиатров. – М., 2007. – С. 524.
Emergence of new forms of totally drug resistant tuberculosis bacilli: super extensively drug resistant tuberculosis or totally drug resistant strains in Iran [The text] / Ali Akbar et al. // Chest. – 2009. – Vol. 136. – P. 420–425.
Fattorini, L. Extensively drug-resistant (XDR) tuberculosis: an old and new threat / Fattorini L., Migliory G.B., Cassone A. // Ann. Ist. Super. Sanita. – 2007. – Vol. 43, №4. – P. 317–319.
Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting / N.R. Gandhi [et al.] // Int. J. Tuberc. Lung Dis. – 2012. – Vol. 1. – P. 90–97.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
